Inovio expects Covid-19 vaccine US trial data by early second quarter

Inovio said it was testing the impact of its vaccine candidate, IN0-4800, on new SARS-CoV-2 variants, as well as developing next-generation Covid-19 vaccine candidates that could be tailored to known and unknown SARS-CoV-2 variants

from mint - News https://ift.tt/3q2sQ2V
https://ift.tt/eA8V8J